Literature DB >> 28868636

Plasma levels of haemostatic factors in patients with pulmonary embolism on admission and seven months later.

M Sane1, M Granér2, J A Laukkanen1,3, V-P Harjola4,5, P Mustonen1.   

Abstract

INTRODUCTION: With the exception of D-dimer, not much is known about the plasma levels of haemostatic factors during acute venous thromboembolism (VTE) compared to their basic levels in a stable phase. The goal of this study was to examine how plasma levels of factor V, VIII, XIIIa, von Willebrand factor antigen (vWF:Ag), fibrinogen, thrombomodulin evolve from the point of diagnosis of acute VTE to the end of standard treatment period.
METHODS: Sixty-three consecutive patients (mean 57, range 18-86 years, 33 females) with acute pulmonary embolism (PE) were included. Laboratory samples were collected upon arrival (acute phase) and seven months later (stable phase). Fifteen similar aged individuals served as controls.
RESULTS: Plasma levels of factor XIIIa (87.5% vs 117.7%, P < .001) and soluble thrombomodulin (36.6 vs 47.5 ng/L, P < .001) were lower, whereas plasma levels of vWF:Ag (2.66 vs 2.01 IU/mL, P < .001) and fibrinogen (4.3 vs 3.9 g/L, P < .05) were higher on admission compared to the stable phase. In the stable phase, vWF:Ag (2.01 vs 1.43 IU/mL, P < .01) and soluble thrombomodulin (47.5 vs 38.0 ng/mL, P < .05), but not FXIIIa levels, were higher in PE patients compared to healthy controls.
CONCLUSION: This study confirms the concept of FXIIIa consumption during acute phase of VTE by showing its intraindividual normalization during the follow-up. vWF:Ag, known to be associated with the risk of VTE, was constantly elevated in the majority of the patients. Soluble thrombomodulin levels were lower in acute phase compared to stable phase, a finding which significance needs to be evaluated in the future.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  coagulation; coagulation factors; factor XIII; pulmonary embolism; venous thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28868636     DOI: 10.1111/ijlh.12729

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  5 in total

1.  Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism.

Authors:  Magnus S Edvardsen; Kristian Hindberg; Ellen-Sofie Hansen; Vânia M Morelli; Thor Ueland; Pål Aukrust; Sigrid K Brækkan; Line H Evensen; John-Bjarne Hansen
Journal:  Blood Adv       Date:  2021-01-12

2.  Identification of thrombomodulin as a dynamic monitoring biomarker for deep venous thrombosis evolution.

Authors:  Xi Cheng; Baolan Sun; Shiyi Liu; Dandan Li; Xiaoqing Yang; Yuquan Zhang
Journal:  Exp Ther Med       Date:  2020-12-14       Impact factor: 2.447

Review 3.  Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism.

Authors:  Michał Ząbczyk; Joanna Natorska; Anetta Undas
Journal:  Int J Mol Sci       Date:  2021-02-05       Impact factor: 5.923

4.  Biomarkers of Thrombo-Inflammatory Responses in Pulmonary Embolism Patients With Pre-Existing Versus New-Onset Atrial Fibrillation.

Authors:  Dimpi Patel; Amir Darki; Debra Hoppensteadt; Iman Darwish; Mushabbar Syed; Yevgeniy Brailovsky; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

5.  Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5.

Authors:  Huriye Ercan; Waltraud Cornelia Schrottmaier; Anita Pirabe; Anna Schmuckenschlager; David Pereyra; Jonas Santol; Erich Pawelka; Marianna T Traugott; Christian Schörgenhofer; Tamara Seitz; Mario Karolyi; Jae-Won Yang; Bernd Jilma; Alexander Zoufaly; Alice Assinger; Maria Zellner
Journal:  Front Cardiovasc Med       Date:  2021-11-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.